ConjuStar

Explore the latest insights on ConjuStar and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of ConjuStar’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

HUTCHMED (China) Limited (NASDAQ: HCM, HKG: 0013) announced that it has initiated the Phase Ia portion of a global clinical trial evaluating HMPL-A830, a potential first‑in‑class antibody‑targeted conjugate (ATTC), for…

September 28, 2026

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

September 28, 2026

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

September 28, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

January 24, 2025

ConjuStar Completes $15 Million Pre-A+ Financing Round

ConjuStar Completes $15 Million Pre-A+ Financing Round

January 17, 2025

ConjuStar Peptide-Drug Conjugate Angel Financing

January 17, 2025